Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > It's a buy ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Post by MrMugsyon Feb 03, 2022 8:09pm
195 Views
Post# 34395542

It's a buy ...

It's a buy ... The "buy" drumbeat could get louder and louder until it's all you can hear.

: )

----------

McAuley estimates Knight will generate full 2021 revenue and EBITDA of $247.0 million and $43.1 million, respectively and 2022 revenue and EBITDA of $290.1 million and $58.7 million, respectively.

McAuley has Knight rated as a “Buy” and a target price of $7.50 per share (both unchanged) for a projected one-year return at the time of publication of 36 per cent.

------------------

Another one of his comments - which is what really draws me to Goodman for a second time ...

(Knight - commercial pharam) engaged in selling approved drug products without such scientific and clinical risks. As well, commercial pharma is an inflation-resistant field due to low material input costs and inelastic product demand.

https://www.cantechletter.com/2022/02/these-two-canadian-pharma-stocks-are-buys-says-paradigm/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities